

Testing quality of a self-monitoring blood glucose sensor with an auto-coding mechanism when used by patients versus technicians

Cheng-Teng Hsu ^{a,*}, Ming-Hsun Wu ^b, Chih-Yi Kuo ^{c,d}, Jyh-Myng Zen ^{e,*}

^a School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan

^b Department of Laboratory Medicine, Min Sheng Hospital, Taoyuan, Taiwan

^c Department of Clinical Laboratory, Tai An Hospital, Taichung, Taiwan

^d Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan

^e Department of Chemistry, National Chung Hsing University, Taichung, Taiwan

ARTICLE INFO

Article history:

Received 30 April 2014

Received in revised form 2 July 2014

Accepted 2 July 2014

Available online 9 July 2014

Keywords:

Self-monitoring of blood glucose (SMBG)

Auto-coding

Miscoding

Patient-derived

User error

ABSTRACT

Background: In response to the problem of erroneous readings due to miscoding when performing self-monitoring blood glucose (SMBG), this study introduces a user-friendly SMBG biosensor with an innovative auto-coding module on the meter and strip. Actual users characterized the performance of the SMBG systems. **Methods:** A total of 105 patients were incorporated in the study and Clarke error grid analysis (EGA) was administered to evaluate the clinical accuracy of the results obtained by the patients versus the technicians. All patients used the questionnaires to comment on the use of the auto-coding sensor.

Results: In the imprecision test, the total CV of the 5 BG levels was 2.1%. In the EGA plot, the results of the auto-coding sensor were 96.2%, both lots A and B, in zone A for the patients and 99.0% and 97.1% for the technician. The paired *t*-test demonstrated no statistically significant difference between the patient and technician measurements. Regression analysis also demonstrated that the measurements taken by the patients agreed with those obtained using the laboratory method.

Conclusions: The patients achieved satisfactory performance using the auto-coding SMBG sensor and derived similar results with both laboratory reference and operation by a technician.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

Self-monitoring of blood glucose (SMBG) is essential for diabetes patients to monitor their glycemia and accordingly moderate their behaviors such as diet and exercise, and is also essential for individuals using insulin or oral agents [1–3]. Regular management of blood glucose (BG) concentration helps patients with type I or type II diabetes by mitigating the onset or progression of diabetic associated complications [4]. The American Diabetes Association (ADA) recommends that individuals with diabetes should routinely monitor their BG level, at least four times daily for those with type I diabetes and once daily for those with type II diabetes [3]. Nevertheless, the monitoring frequency of BG level using SMBG biosensor remains well below the level suggested by ADA. Possible reasons for this situation include pain resulting from skin puncture, difficulty in inserting test strips, trouble applying sufficient blood volume, and questions regarding test accuracy, all of which create enormous demand for more user-friendly BG sensors [5].

Skeie et al. assessed the quality of five different SMBG systems and observed significant differences between the BG values performed by

patients and technicians [6]. Compared to the values obtained using the laboratory method, the analytical results obtained by the technicians were more accurate than those obtained by the patients. Another investigation by Kristensen et al. showed that the measurements taken by the patients deviated more from the limits required by the ISO standard than did those taken by the technicians [7]. SMBG manufacturers have examined the discrepancies between the results obtained by patients and technicians when operating SMBG systems. These discrepancies are primarily attributable to the special usage techniques associated with the SMBG system, the background knowledge of users, and the robustness of SMBG systems. The quality of SMBG systems is limited by current technology, which requires strict operating techniques for SMBG systems to ensure accurate outcomes. Techniques applied to SMBG systems include, but are not limited to, cleaning the fingertips before puncturing the skin, using the systems under appropriate ambient conditions, using the test strips with the corresponding calibration codes, and applying sufficient blood to the test strips. Earlier investigations found that 16% of 183 patients [7] and 16% of 201 patients [8] used incorrect codes for SMBG operation during a single clinic visit. This incidence of miscoding has placed a strong focus on caregivers. Baum et al. designed an experiment to compare the analytical results obtained from incorrectly and correctly coded SMBG systems [9]. They concluded that the analytical errors associated with incorrectly coded

* Corresponding authors.

E-mail addresses: a629405@ms27.hinet.net (C.-T. Hsu), jmzen@dragon.nchu.edu.tw (J.-M. Zen).

systems exceeded $\pm 30\%$. A simulation of insulin dosage based on miscoded SMBG systems further demonstrated the importance of coding systems for patients undergoing insulin administration [10,11].

Most of the commercially available amperometric type SMBG biosensors are calibrated using code chip/code key or manual coding. In the case of manual-coding biosensors operated via a single button, users must press and hold that button to go over all the codes until the correct one shows up. On the appearance of the correct code, the button must be immediately released to avoid missing the correct code. Otherwise, the user must repeat the whole process. These processes are intended to protect patients against misleading BG information; however, such complex and time consuming processes may discourage them from performing SMBG.

2. Materials and methods

2.1. SMBG instrument with auto-coding mechanism

This study applied an SMBG biosensor, Bionime Rightest GM550 (Bionime Corp) that incorporated an innovative auto-coding module on the meter and strip. The coding module on the meter is assembled with code pin, rubber, grounding material, ball, and spring, all assembled in series. Each code pin engages with the specific flat or concave hole on the strip and can then define to binary coding information, 1 or 0, which the black pins embedded into concave holes on the strip represent binary coding 1, while the white pins embedded into flat holes on the strip represent binary coding 0. The combination of all the binary coding information can obtain a predefined parameter from the meter. The strip contains 12 code pins and can thus provide up to 2^{12} combinations of coding patterns. Each test strip in the same lot has the same code pattern and each lot is assigned a specific parameter. By precisely detecting the combinative coding pattern, the auto-coding sensor can automatically perform calibration using a single defined parameter. This function markedly reduces errors in usage technique that result from miscoding.

2.2. Subjects

A total of 105 diabetes and non-diabetes participants (44 males and 61 females from 24 to 87 years old) were enrolled in this clinical study at Min-Sheng General Hospital, Taoyuan City, Taiwan. The study participants were not necessarily users of the auto-coding BG monitors. The protocol was approved by the Institutional Review Boards for studies involving human subjects (MSEIRB Authority No. 0980110) with the informed consent of all participants. All participants were asked to provide information on their age, gender, type of diabetes, duration of personal diabetic history and time using BG sensors. At the end of the test, participants also completed a questionnaire on their experience of using the auto-coding BG sensor during the clinical study.

2.3. Test procedure

The imprecision test of the auto-coding sensor was assessed by a technician using two strip lots, A and B. Venous blood samples were collected via venipuncture and spiked at five glucose concentration levels. A hundred measurements were taken from 10 meters with 10 replicates at each glucose level, and 1000 measurements were obtained by the completion of testing.

The general procedures used to evaluate clinical accuracy are as follows: (1) a patient received basic instructions regarding SMBG before the tests; (2) after reading these instructions, a 200- μ l of capillary blood was collected from the fingertip of the patient by a technician and centrifuged. The BG value of the plasma was measured using the hexokinase method (Olympus AU640 Clinical Analyzer, laboratory reference method); (3) on completion of the blood collection, the patient performed SMBG themselves and obtained two measurements, strip lots A and B, respectively; (4) two further measurements with strip

lots A and B were obtained by the technician immediately after the patient finished SMBG; (5) immediately after the technician obtained the two measurements, an additional 200- μ l of capillary blood was collected from their fingertip. The capillary blood was centrifuged and the BG value of plasma was measured using the laboratory reference method. Steps (1) to (5) were repeated for all 105 patients. Imprecision test and clinical accuracy evaluation were performed according to ISO 15197:2003 [12].

2.4. Statistical analysis

The imprecision was expressed in terms of the coefficient of variation (CV). The pooled imprecision at each glucose concentration level was determined by including measurements from strip lots A and B in the calculation, and the total imprecision expressed in terms of the overall testing range was calculated using all the measured test values. The Clarke error grid analysis (EGA) was conducted to evaluate the clinical accuracy of the auto-coding sensor compared to the reference method [13,14]. The Clarke EGA requires over 95% of the BG measurements to fall within zone A and 100% to fall within zone A+B. EGA contains 5 zones (A, B, C, D, and E). Zone A represents bias within 20% of reference values or the hypoglycemic region. Zone B denotes bias outside of 20% of the reference values but no/benign treating effect. Values in zones C, D, and E may cause unnecessary corrective treatments, failure to administer treatment, and incorrect treatment, respectively. Notably, results within zones A or B are clinically acceptable, whereas those within zones C, D, or E are completely intolerable. In this investigation, the agreement between whole blood glucose values obtained from meters and plasma BG values obtained from the laboratory reference method was further assessed via regression analysis.

3. Results

3.1. Imprecision test

Table 1 lists the results of the imprecision test with strip lots A and B. The pooled CVs of the auto-coding BG sensor were 2.0% and 1.9% at the lowest and highest BG levels, respectively. At levels II, III and IV, the pooled CVs of the auto-coding BG sensor were 1.3%, 1.2%, and 1.8%, respectively.

3.2. Clinical accuracy evaluation

The clinical accuracy assessment of the Bionime Rightest GM550 biosensor with two strip lots (lot A and B) was conducted by the patients and the technician, and the results were determined based on the Clarke EGA. Table 2 lists the percentages of measurements that fall within zones A and A+B in the EGA plot. The results of the auto-coding BG sensor were 96.2%, both lots A and B, in zone A when operated by the patients, and 99.0% and 97.1% when operated by the technician. No results fell in zones C, D, or E. Furthermore, the paired *t*-test for comparing the results obtained by the patients and the technician (i.e. *p*-value) obtained results of 0.84 and 0.49 for lots A and B, respectively. Fig. 1(A) presents regression analysis comparing the results obtained from the patients and the technician with those obtained using the reference method in the EGA plot, where the slope and intercept were 0.94 and -1.26 by patients, and 0.95 and -3.88 by the technician. Fig. 1(B) illustrates the correlation between the results obtained by the patients and the technician. The slope and intercept was 0.99 and 0.16.

3.3. Questionnaire responses

Table 3 shows the statistics obtained from the questionnaire in relation to patient SMBG characteristics and patterns. Some 53.6% of diabetes patients claimed experience of using SMBG sensor. Moreover, up to 93.3% of participants were satisfied with the auto-coding function of the

Table 1
Imprecision evaluation of the Bionime Rightest GM550 biosensor.

Glucose concentration	Mean (mmol/l)		SD (mmol/l)		CV (%)		
	Strip lot A	Strip lot B	Strip lot A	Strip lot B	Strip lot A	Strip lot B	Pooled
Level I (1.7–2.8 mmol/l)	2.4	2.3	0.04	0.05	1.8	2.1	2.0
Level II (2.9–6.1 mmol/l)	5.6	5.2	0.06	0.07	1.1	1.4	1.3
Level III (6.2–8.3 mmol/l)	7.8	7.4	0.09	0.09	1.1	1.2	1.2
Level IV (8.4–13.9 mmol/l)	11.5	11.2	0.19	0.21	1.7	1.9	1.8
Level V (14.0–22.2 mmol/l)	20.8	16.7	0.36	0.36	1.7	2.2	1.9
Total					1.9	2.2	2.1

A hundred venous blood measurements were performed at each level for each lot, for a total of 1000 measurements.

Bionime Rightest GM550 biosensor. The percentage of operators performing coding correctly before the measurement was 100%.

4. Discussion

Performance testing of SMBG systems should involve real users. This investigation thus conducted performance testing of the SMBG system using non-technicians, and obtained feedback from these users via a questionnaire.

The auto-coding biosensor achieved excellent performance in the imprecision test. The total CV of the 5 BG levels was 2.1% (Table 1). In the highest and lowest BG levels, which are essential for monitoring hyper- and hypoglycemia, the pooled CVs exhibited high precision, of 1.9 and 2.0%, respectively.

For electrochemical sensors, the variations in normal manufacturing tolerances include electrode size, reagent deposited, reagent reactivity such as rate of dissolution and enzyme activity, and micro-differences in geometry, which cause so-called lot-to-lot variations [15,16]. To compensate for such variations, a specific code is provided to calibrate the sensor for the relevant strip lot. This approach enables patients to use/select a specific code chip or code key to derive an accurate mapping of electrochemical current and accurate BG concentration. However, inaccurate BG concentration derives from incorrectly coded sensors [7,8]. The auto-coding module of the GM500 device is designed to incorporate the traditional code chip or code key into the meter and test strip, which means each test strip is also a code chip and can be instantly recognized when inserted into the meter without any further calibration procedure. This design significantly reduces the probability of miscoding and the time spent in traditional calibration process. In this study the analytical results of SMBG handled by the patients exhibited no difference between lots A and B (Table 2). This proves that lot-to-lot variations barely influenced the accuracy of the auto-coding biosensor with actual users.

Previous studies demonstrated that the measurements taken by patients deviated from the laboratory measurements more than did those taken by the technicians [6,7]. However, as shown in Fig. 1(A), both patients and technicians obtained accurate measurements, assessed using the reference instrument as a yardstick. More than 95% of the measurements performed by patients fell within zone A of the EGA (Table 2, Fig. 1A), indicating that reducing the technical difficulties of using SMBG meters, increased the accuracy of the results obtained when the device was operated by real world users.

Table 2
Percentages of the SMBG values within the EGA zones.

Strip lot	Patients		Technician		Paired <i>t</i> -test (patients vs. technician)
	Within zone in EGA plot				
	A	A+B	A	A+B	
A	96.2%	100.0%	99.0%	100.0%	<i>p</i> = 0.84
B	96.2%	100.0%	97.1%	100.0%	<i>p</i> = 0.49

The patients and the technician provided nearly identical analytical results, with a square of correlation coefficient of 0.98 (Fig. 1B). The square of correlation coefficient of 0.98 indicated good agreement between the results obtained from the patients and the technician. The paired *t*-test, *p* = 0.84 and 0.49 for lots A and B respectively (Table 2), demonstrated no statistically significant difference between the measurements obtained from the patients and the technician. The accuracy




Fig. 1. Scatter plot of (A) the capillary BG results obtained from the patients (○) and technician (▲), 105 measurements each, compared to those obtained using the reference method (Olympus AU640) plotted in EGA with linear regression analysis; definitions of the Clarke EGA zones: zone A (no effect on clinical action); zone B (little or no effect on clinical outcome); zone C (likely to affect clinical outcome); zone D (could have significant medical risk); zone E (could have dangerous consequences); (B) linear regression analysis for the BG measurements obtained when the device was operated by the patients compared to those obtained by the technician (*n* = 105).

Table 3

Patient responses to the questionnaire regarding the SMBG sensor.

Patients (<i>n</i> = 105), %	
With diabetes	78.1
Unknown	21.9
Duration of diabetes (mean ± SD), in years	8.7 ± 9.1
Use of BG sensor among diabetes patients	
The percentage for the use of BG sensor, %	53.6
Total duration of SMBG (mean ± SD), in years	5.5 ± 4.3
Percentages of coding correctly, %	
Rightest GM 550	100
Satisfactory level for GM550 with auto-coding function, %	
Highly unsatisfactory	0
Unsatisfactory	1
Acceptable	5.7
Satisfactory	41.9
Highly satisfactory	51.4
Satisfactory level for overall design of GM550, %	
Satisfactory or more	92.4

of the BG measurements of the patients, which was attributed to the auto-coding mechanism having excluded the technical difficulties associated with selecting the correct code for the corresponding strips, was improved. Notably, in the EGA plot (Fig. 1A), higher bias of BG values in upper zone B was observed and recorded immediately after measurement by one patient. This larger bias resulted from the user collecting blood twice, an incorrect operation, and could have been avoided via better user instruction and education.

All 105 questionnaire responses were obtained after each patient performed SMBG using the auto-coding biosensor. Over 93% of the patients achieved satisfactory or highly satisfactory performance using the auto-coding function (Table 3). Notably, one participant who claimed to be used to the manual coding function could not adapt to the new auto-coding function, and hence classified it as unsatisfactory. The percentage of correctly coded meters was 100%, since the auto-coding meters did not have to change any code numbers.

Besides the innovation of the SBMG devices, educating diabetes patients to learn how to perform SMBG correctly is another strategy to improve measurement quality [17–20]. In a questionnaire completed by 422 patients, 51% of those patients were self-educated in performing SMBG, and only 2% had been trained by a physician [6]. More interestingly, the questionnaire demonstrated that 74% of the patients never or rarely questioned the accuracy of their SMBG systems. These percentages raise a serious concern; if any technical error, such as miscoding, should occur during the performance of SMBG without being noticed by a patient, and should result in an erroneous measurement, that measurement could cause the patient unnecessary anxiety. Still worse, the patient is likely to use the wrong measurement to undertake inappropriate clinical action. Physicians, caregivers and well-trained SMBG technicians thus should be more active in SMBG education for diabetes patients.

5. Conclusions

The SMBG sensor with the auto-coding function was implemented on a group of patients and its quality demonstrated. The auto-coding mechanism, which involves a specific code pattern on the strip and sensitive code module on the meter, largely resolved the technical challenges associated with SMBG and decreased the likelihood of miscoding by the SMBG performers. The BG values obtained from the patients exhibited high clinical accuracy and no statistical difference compared with those obtained by a well-trained technician. The measurements taken by the patients

also exhibited good agreement with those obtained using the laboratory instruments. The auto-coding SMBG sensor thus obtained satisfactory results when applied to diabetes patients. We believe the improvements in BG biosensors in relation to user-friendly functions will encourage and support more diabetes patients to perform SMBG.

Abbreviations

SMBG	self-monitoring of blood glucose
BG	blood glucose
ADA	American Diabetes Association
ISO	International Organization for Standardization
EGA	error grid analysis.

Acknowledgments

We thank all the technical staff from the research and development division of Bionime Corp. for their helpful suggestions, as well as the nurses at Min-Sheng General Hospital for their technical assistance. Brian Ma and Ta-Yu Huang are also appreciated for their assistance in drafting the manuscript. Ted Knoy is appreciated for his editorial assistance.

References

- [1] Consensus statement on self-monitoring of blood glucose. *Diabetes Care* 1987;10:95–9.
- [2] Schwedes U, Siebolds M, Mertes G, Group SS. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. *Diabetes Care* 2002;25:1928–32.
- [3] American Diabetes Association. Standards of medical care in diabetes—2009. *Diabetes Care* 2009;32:S13–61.
- [4] Blonde L, Karter AJ. Current evidence regarding the value of self-monitored blood glucose testing. *Am J Med* 2005;118:205–6S.
- [5] Burney M. Growing demand yields 'friendlier' blood sugar monitors. *Hosp Mater Manage* 1998;23:14.
- [6] Skeie S, Thue G, Nerhus K, Sandberg S. Instruments for self-monitoring of blood glucose: comparisons of testing quality achieved by patients and a technician. *Clin Chem* 2002;48:994–1003.
- [7] Kristensen GB, Nerhus K, Thue G, Sandberg S. Standardized evaluation of instruments for self-monitoring of blood glucose by patients and a technologist. *Clin Chem* 2004;50:1068–71.
- [8] Raine III CH. Self-monitored blood glucose: a common pitfall. *Endocr Pract* 2003;9:137–9.
- [9] Baum JM, Monhaut NM, Parker DR, Price CP. Improving the quality of self-monitoring blood glucose measurement: a study in reducing calibration errors. *Diabetes Technol Ther* 2006;8:347–57.
- [10] Raine III CH, Pardo S, Parkes JL. Predicted blood glucose from insulin administration based on values from miscoded glucose meters. *J Diabetes Sci Technol* 2008;2:557–62.
- [11] Raine III CH, Schrock LE, Edelman SV, et al. Significant insulin dose errors may occur if blood glucose results are obtained from miscoded meters. *J Diabetes Sci Technol* 2007;1:205–10.
- [12] ISO 15197:2003(E). ISO 15197 *in vitro* diagnostic test systems—requirements for blood-glucose monitoring system for self-testing in managing diabetes mellitus. Geneva: International Standards Organization; 2003.
- [13] Clarke WL. The original Clarke error grid analysis (EGA). *Diabetes Technol Ther* 2005;7:776–9.
- [14] Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. *Diabetes Care* 1987;10:622–8.
- [15] Hsu CT, Chung HH, Tsai DM, Fang MY, Hsiao HC, Zen JM. Fabrication of a glucose biosensor based on inserted barrel plating gold electrodes. *Anal Chem* 2009;81:515–8.
- [16] Hsu CT, Hsiao HC, Fang MY, Zen JM. Superior long-term stability of a glucose biosensor based on inserted barrel plating gold electrodes. *Biosens Bioelectron* 2009;25:383–7.
- [17] Proposed strategies for reducing user error in capillary blood glucose monitoring. The National Steering Committee for Quality Assurance in Capillary Blood Glucose Monitoring. *Diabetes Care* 1993;16:493–8.
- [18] Bergenstal R, Pearson J, Cembrowski GS, Bina D, Davidson J, List S. Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy. *Diabetes Educ* 2000;26:981–9.
- [19] Nattrass M. Improving results from home blood-glucose monitoring: accuracy and reliability require greater patient education as well as improved technology. *Clin Chem* 2002;48:979–80.
- [20] Gallichan M. Self monitoring of glucose by people with diabetes: evidence based practice. *BMJ* 1997;314:964–7.